Voyager Therapeutics (VYGR) Expected to Announce Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR) is expected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Voyager Therapeutics to post earnings of ($0.53) per share and revenue of $7.8580 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Stock Performance

VYGR traded down $0.11 on Tuesday, reaching $4.48. The company had a trading volume of 84,667 shares, compared to its average volume of 573,495. The business has a 50 day simple moving average of $4.44 and a 200 day simple moving average of $3.68. The company has a market cap of $248.73 million, a price-to-earnings ratio of -2.42 and a beta of 0.95. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $7.44.

Insider Activity

In other news, CFO Nathan D. Jorgensen sold 7,666 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer owned 123,834 shares in the company, valued at approximately $591,926.52. This trade represents a 5.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VYGR. Occudo Quantitative Strategies LP bought a new position in shares of Voyager Therapeutics in the second quarter worth approximately $78,000. Jane Street Group LLC lifted its stake in Voyager Therapeutics by 92.6% in the second quarter. Jane Street Group LLC now owns 27,844 shares of the company’s stock worth $87,000 after acquiring an additional 13,389 shares during the period. Invesco Ltd. lifted its stake in Voyager Therapeutics by 30.4% in the second quarter. Invesco Ltd. now owns 63,298 shares of the company’s stock worth $197,000 after acquiring an additional 14,758 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Voyager Therapeutics in the first quarter worth $218,000. Finally, American Century Companies Inc. lifted its stake in Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after acquiring an additional 6,748 shares during the period. Institutional investors own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on VYGR. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, September 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush reduced their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.96.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.